Pyrrolo<2.3-b>pyrrol | 58326-34-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Pyrrolo<2.3-b>pyrrol
• 英文别名: 1H,6H-Pyrrolo<2,3-b>pyrrol；3-O-feruloylquinic acid 4'-sulfate；1,6-dihydro-pyrrolo[2,3-b]pyrrole；1,6-Dihydropyrrolo[2,3-b]pyrrole
• CAS: 58326-34-4
• 化学式: C₆H₆N₂
• mdl: MFCD10699407
• 分子量: 106.127
• InChiKey: CGRCTJNCJNTKKL-UHFFFAOYSA-N

物化性质

• 沸点：
  312.0±15.0 °C(Predicted)
• 密度：
  1.323±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  31.6
• 氢给体数：
  2
• 氢受体数：
  0

文献信息

• [EN] SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS DE DCN1 À PETITES MOLÉCULES ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2018183411A1

  公开（公告）日：2018-10-04

  Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  公式（I）的化合物被披露为DCNl的抑制剂，以及含有这些化合物的组合物。还披露了在治疗疾病和病况中使用DCNl抑制剂的方法，其中DCNl的抑制提供益处，如氧化应激相关的疾病和病况、神经退行性疾病和病况、代谢紊乱以及肌肉神经退化。
• Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20180289677A1

  公开（公告）日：2018-10-11

  Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  揭示了DCN1的小分子共价抑制剂和含有这些抑制剂的组合物。还揭示了在治疗疾病和状况中使用DCN1共价抑制剂的方法，其中DCN1的抑制提供益处，如氧化应激相关的疾病和状况、神经退行性疾病和状况、代谢紊乱以及肌肉神经退化。
• SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I
  申请人：Fink Marc David

  公开号：US20070299112A1

  公开（公告）日：2007-12-27

  The present invention discloses and claims compounds of formula (I) and formula (II), as inhibitors of human casein kinase Iε and methods for using said compounds for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) or formula (II) and a method for the preparation of compounds of formula (I) or formula (II) are also disclosed and claimed.

  本发明揭示和声明公式(I)和公式(II)的化合物，作为人类酪蛋白激酶Iε的抑制剂，并提供使用这些化合物治疗中枢神经系统疾病和紊乱，包括情绪障碍和睡眠障碍的方法。还揭示和声明了包含公式(I)或公式(II)化合物的药物组合物，以及制备公式(I)或公式(II)化合物的方法。
• [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
  申请人：HARVARD COLLEGE

  公开号：WO2015103583A1

  公开（公告）日：2015-07-09

  Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.

  本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II')，以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。
• Compounds For The Treatment Of Neuromuscular Disorders
  申请人：NMD Pharma ApS

  公开号：US20190185437A1

  公开（公告）日：2019-06-20

  The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel.

  本发明涉及适用于治疗、改善和/或预防神经肌肉疾病的化合物，包括逆转药物诱导的神经肌肉阻滞。所述化合物如本文所定义，优选抑制ClC-1离子通道。